US Stock MarketDetailed Quotes

CRSP CRISPR Therapeutics

Watchlist
  • 46.290
  • -0.970-2.05%
Close Nov 21 16:00 ET
  • 46.785
  • +0.495+1.07%
Post 20:01 ET
3.95BMarket Cap-16591P/E (TTM)

CRISPR Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-168.25%-106.91M
28.27%-95.58M
1,147.32%109.75M
47.48%-260.38M
15.23%-96.07M
62.12%-39.86M
6.14%-133.25M
106.51%8.8M
-191.98%-495.74M
-31.72%-113.33M
Net income from continuing operations
23.37%-85.94M
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
Depreciation and amortization
-3.78%4.74M
-2.34%4.85M
-4.32%4.83M
-17.93%19.84M
-16.18%4.9M
-1.85%4.93M
-31.75%4.96M
-16.36%5.05M
34.64%24.17M
-6.63%5.85M
Other non cash items
-33.69%-6.9M
-159.63%-8.18M
-765.33%-8.39M
-212.63%-14.05M
-2,276.26%-4.77M
-299.96%-5.16M
-188.21%-3.15M
-115.89%-969K
-11.62%12.47M
-95.33%219K
Change In working capital
-176.78%-40.36M
113.27%10.49M
470.33%210.49M
-1,075.49%-193.59M
-545.02%-203.97M
41.34%52.56M
-1,066.16%-79.08M
505.53%36.91M
-26.11%19.85M
-271.01%-31.62M
-Change in receivables
--0
--0
--200M
-65,673.77%-200M
-408,263.27%-200M
411,664.71%70M
-91,009.09%-70M
--0
289.44%305K
132.03%49K
-Change in prepaid assets
-123.01%-188K
-39.98%2.35M
-75.51%2.95M
1,353.00%23.22M
218.05%6.45M
-83.76%817K
251.69%3.91M
161.11%12.04M
111.49%1.6M
-212.36%-5.46M
-Change in payables and accrued expense
-54.53%-38.16M
180.17%9.28M
-62.55%9.44M
-492.08%-20.25M
70.44%-9.19M
-188.32%-24.69M
-216.72%-11.58M
1,660.27%25.21M
-86.23%5.16M
-236.50%-31.1M
-Change in other current liabilities
128.18%31K
112.70%40K
-154.12%-432K
107.23%110K
7.80%705K
89.29%-110K
68.31%-315K
-10.39%-170K
71.33%-1.52M
-44.48%654K
-Change in other working capital
-131.19%-2.04M
-7.18%-1.18M
-730.51%-1.47M
-76.69%3.33M
-145.76%-1.94M
25.68%6.55M
-162.43%-1.1M
-105.72%-177K
63.92%14.3M
141.61%4.24M
Cash from discontinued investing activities
Operating cash flow
-168.25%-106.91M
28.27%-95.58M
1,147.32%109.75M
47.48%-260.38M
15.23%-96.07M
62.12%-39.86M
6.14%-133.25M
106.51%8.8M
-191.98%-495.74M
-31.72%-113.33M
Investing cash flow
Cash flow from continuing investing activities
-233.17%-161.6M
-158.50%-126.91M
-183.00%-97.8M
244.84%374.65M
53.60%-81.45M
38.74%121.35M
486.87%216.92M
202.89%117.83M
75.02%-258.66M
-1,913.91%-175.53M
Net PPE purchase and sale
89.66%-219K
80.11%-707K
76.43%-721K
74.53%-9.47M
88.08%-738K
64.80%-2.12M
63.08%-3.56M
80.07%-3.06M
54.49%-37.19M
32.58%-6.19M
Net intangibles purchase and sale
--0
----
----
---2.5M
--0
---1M
----
----
--0
--0
Net investment purchase and sale
-229.66%-161.39M
-156.85%-126.2M
-180.30%-97.08M
274.57%386.62M
52.34%-80.72M
33.15%124.47M
577.97%221.98M
221.91%120.89M
76.78%-221.47M
-36,361.46%-169.34M
Cash from discontinued investing activities
Investing cash flow
-233.17%-161.6M
-158.50%-126.91M
-183.00%-97.8M
244.84%374.65M
53.60%-81.45M
38.74%121.35M
486.87%216.92M
202.89%117.83M
75.02%-258.66M
-1,913.91%-175.53M
Financing cash flow
Cash flow from continuing financing activities
519.54%9.64M
-102.78%-466K
5,561.25%305.93M
62.38%62.66M
1,471.39%38.94M
-89.70%1.56M
61.93%16.77M
-49.25%5.4M
-84.62%38.59M
-60.66%2.48M
Net common stock issuance
--6M
---1.01M
--280.75M
3,273.30%32.72M
--32.72M
--0
--0
--0
-99.55%970K
--0
Proceeds from stock option exercised by employees
133.74%3.64M
-96.74%546K
366.12%25.19M
-20.41%29.94M
150.93%6.22M
-89.00%1.56M
61.93%16.77M
-49.25%5.4M
-0.15%37.62M
-60.66%2.48M
Cash from discontinued financing activities
Financing cash flow
519.54%9.64M
-102.78%-466K
5,561.25%305.93M
62.38%62.66M
1,471.39%38.94M
-89.70%1.56M
61.93%16.77M
-49.25%5.4M
-84.62%38.59M
-60.66%2.48M
Net cash flow
Beginning cash position
8.63%495.99M
101.88%718.94M
79.00%401.07M
-76.16%224.06M
5.74%539.6M
-11.01%456.6M
-49.18%356.12M
-76.16%224.06M
-20.71%939.94M
-50.38%510.33M
Current changes in cash
-411.72%-258.88M
-321.97%-222.95M
140.76%317.89M
124.72%176.94M
51.61%-138.59M
3,243.38%83.05M
153.52%100.44M
155.22%132.03M
-191.55%-715.8M
-223.76%-286.38M
Effect of exchange rate changes
256.25%75K
-92.86%2K
-134.38%-11K
191.25%73K
-46.96%61K
52.00%-48K
141.18%28K
218.52%32K
-627.27%-80K
3,733.33%115K
End cash Position
-56.04%237.19M
8.63%495.99M
101.88%718.94M
79.00%401.07M
79.00%401.07M
5.74%539.6M
-11.01%456.6M
-49.18%356.12M
-76.16%224.06M
-76.16%224.06M
Free cash flow
-149.29%-107.13M
30.38%-96.29M
1,799.49%109.03M
48.90%-272.35M
19.00%-96.81M
61.37%-42.97M
8.76%-138.3M
103.81%5.74M
-216.55%-532.93M
-25.52%-119.52M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -168.25%-106.91M28.27%-95.58M1,147.32%109.75M47.48%-260.38M15.23%-96.07M62.12%-39.86M6.14%-133.25M106.51%8.8M-191.98%-495.74M-31.72%-113.33M
Net income from continuing operations 23.37%-85.94M-62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M
Depreciation and amortization -3.78%4.74M-2.34%4.85M-4.32%4.83M-17.93%19.84M-16.18%4.9M-1.85%4.93M-31.75%4.96M-16.36%5.05M34.64%24.17M-6.63%5.85M
Other non cash items -33.69%-6.9M-159.63%-8.18M-765.33%-8.39M-212.63%-14.05M-2,276.26%-4.77M-299.96%-5.16M-188.21%-3.15M-115.89%-969K-11.62%12.47M-95.33%219K
Change In working capital -176.78%-40.36M113.27%10.49M470.33%210.49M-1,075.49%-193.59M-545.02%-203.97M41.34%52.56M-1,066.16%-79.08M505.53%36.91M-26.11%19.85M-271.01%-31.62M
-Change in receivables --0--0--200M-65,673.77%-200M-408,263.27%-200M411,664.71%70M-91,009.09%-70M--0289.44%305K132.03%49K
-Change in prepaid assets -123.01%-188K-39.98%2.35M-75.51%2.95M1,353.00%23.22M218.05%6.45M-83.76%817K251.69%3.91M161.11%12.04M111.49%1.6M-212.36%-5.46M
-Change in payables and accrued expense -54.53%-38.16M180.17%9.28M-62.55%9.44M-492.08%-20.25M70.44%-9.19M-188.32%-24.69M-216.72%-11.58M1,660.27%25.21M-86.23%5.16M-236.50%-31.1M
-Change in other current liabilities 128.18%31K112.70%40K-154.12%-432K107.23%110K7.80%705K89.29%-110K68.31%-315K-10.39%-170K71.33%-1.52M-44.48%654K
-Change in other working capital -131.19%-2.04M-7.18%-1.18M-730.51%-1.47M-76.69%3.33M-145.76%-1.94M25.68%6.55M-162.43%-1.1M-105.72%-177K63.92%14.3M141.61%4.24M
Cash from discontinued investing activities
Operating cash flow -168.25%-106.91M28.27%-95.58M1,147.32%109.75M47.48%-260.38M15.23%-96.07M62.12%-39.86M6.14%-133.25M106.51%8.8M-191.98%-495.74M-31.72%-113.33M
Investing cash flow
Cash flow from continuing investing activities -233.17%-161.6M-158.50%-126.91M-183.00%-97.8M244.84%374.65M53.60%-81.45M38.74%121.35M486.87%216.92M202.89%117.83M75.02%-258.66M-1,913.91%-175.53M
Net PPE purchase and sale 89.66%-219K80.11%-707K76.43%-721K74.53%-9.47M88.08%-738K64.80%-2.12M63.08%-3.56M80.07%-3.06M54.49%-37.19M32.58%-6.19M
Net intangibles purchase and sale --0-----------2.5M--0---1M----------0--0
Net investment purchase and sale -229.66%-161.39M-156.85%-126.2M-180.30%-97.08M274.57%386.62M52.34%-80.72M33.15%124.47M577.97%221.98M221.91%120.89M76.78%-221.47M-36,361.46%-169.34M
Cash from discontinued investing activities
Investing cash flow -233.17%-161.6M-158.50%-126.91M-183.00%-97.8M244.84%374.65M53.60%-81.45M38.74%121.35M486.87%216.92M202.89%117.83M75.02%-258.66M-1,913.91%-175.53M
Financing cash flow
Cash flow from continuing financing activities 519.54%9.64M-102.78%-466K5,561.25%305.93M62.38%62.66M1,471.39%38.94M-89.70%1.56M61.93%16.77M-49.25%5.4M-84.62%38.59M-60.66%2.48M
Net common stock issuance --6M---1.01M--280.75M3,273.30%32.72M--32.72M--0--0--0-99.55%970K--0
Proceeds from stock option exercised by employees 133.74%3.64M-96.74%546K366.12%25.19M-20.41%29.94M150.93%6.22M-89.00%1.56M61.93%16.77M-49.25%5.4M-0.15%37.62M-60.66%2.48M
Cash from discontinued financing activities
Financing cash flow 519.54%9.64M-102.78%-466K5,561.25%305.93M62.38%62.66M1,471.39%38.94M-89.70%1.56M61.93%16.77M-49.25%5.4M-84.62%38.59M-60.66%2.48M
Net cash flow
Beginning cash position 8.63%495.99M101.88%718.94M79.00%401.07M-76.16%224.06M5.74%539.6M-11.01%456.6M-49.18%356.12M-76.16%224.06M-20.71%939.94M-50.38%510.33M
Current changes in cash -411.72%-258.88M-321.97%-222.95M140.76%317.89M124.72%176.94M51.61%-138.59M3,243.38%83.05M153.52%100.44M155.22%132.03M-191.55%-715.8M-223.76%-286.38M
Effect of exchange rate changes 256.25%75K-92.86%2K-134.38%-11K191.25%73K-46.96%61K52.00%-48K141.18%28K218.52%32K-627.27%-80K3,733.33%115K
End cash Position -56.04%237.19M8.63%495.99M101.88%718.94M79.00%401.07M79.00%401.07M5.74%539.6M-11.01%456.6M-49.18%356.12M-76.16%224.06M-76.16%224.06M
Free cash flow -149.29%-107.13M30.38%-96.29M1,799.49%109.03M48.90%-272.35M19.00%-96.81M61.37%-42.97M8.76%-138.3M103.81%5.74M-216.55%-532.93M-25.52%-119.52M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Gene Editing
Gene Editing
Intraday+0.44%
ARK Portfolio
ARK Portfolio
Intraday-0.69%